Choksi Laborator (526546)
Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1
Key Financials
| Current Price | ₹61.93 |
| Market Cap | ₹43.14 Cr |
| P/E Ratio | 48.6 |
| ROCE | 9.2% |
| ROE | 8.07% |
| Dividend Yield | 0% |
| Profit Growth | -63.64% |
| Debt/Equity | — |
| Sales Growth | 4.24% |
| 52-Week Range | ₹81.85 — ₹160.25 |
| Sector | Healthcare Services |
| Book Value | ₹38.13 |
AI Analysis
AI-generated, general educational analysis — not personal investment advice.
Looking at Choksi Laborator, I am reminded of the importance of a margin of safety. The market cap is only ₹43 crore, and the shares trade at ₹61.93—well below the 52-week low of ₹81.85 and more than 70% off the high of ₹236.70. That looks like deep distress, not necessarily deep value. The business earns only 8.07% on equity and 9.20% on capital employed; these are not catastrophic, but they are far from the consistent high returns I seek. A P/E of 48.60 makes little sense when profit growth has collapsed by 63.64%, and the PEG ratio of 11.46 tells me the market is pricing in miracles. The latest quarter shows sales of ₹11 crore but zero net profit, so the earnings power is currently not visible. Sales growth is a modest 4.24%, hardly evidence of a strong franchise. There is no dividend to cushion the wait. The Piotroski score of 4 out of 9 suggests weak overall financial health, and with debt/equity not disclosed, I cannot credit management with a clean balance sheet. Book value of ₹38.13 gives a P/B of 1.62, but a subpar ROE means the book value is not generating much wealth for shareholders. In Graham's terms, I want a stable earnings record, financial strength, and a reasonable price. Choksi is small, its profit has vanished, and its trading range shows severe volatility. This is not an investment; it is at best a speculation on a turnaround. The price may look tempting after a fall, but without evidence of recovering margins, improving returns, and honest capital allocation, I would rather watch from the sidelines. Numbers speak; these numbers tell me to wait.
The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.
Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer